Exhibit 10.4

Amendment No. 3, dated as of the 4th day of June, 2010 (Amendment No. 3), to a certain Patent Assignment And
License Agreement, dated May 21, 2008, as amended and/or supplemented by Amendment No. 1 dated October 9, 2008, Patent Assignment dated November 3, 2008, and Amendment No. 2 dated June 18, 2009 (collectively, the
Agreement), by and between Ribotask ApS, having its offices at Unsbjergvej 2A, 5220 Odense SØ, Denmark, being a corporation established under the laws of Denmark (Assignor), and MDRNA, Inc. (f/k/a Nastech
Pharmaceutical Company Inc.), having its offices at 3830 Monte Villa Pkwy, Bothell, WA 98021, being a corporation established under the laws of the State of Delaware, United States of America (Assignee).

WHEREAS, the parties wish to modify the Agreement as set forth herein;

NOW, THEREFORE, in consideration of the premises and mutual covenants set forth herein, the parties hereto hereby agree as follows:

1. Assignor hereby acknowledges and confirms that all amounts which have become due from Assignee on or prior to the date of this Amendment
No. 3 have been paid in full and that Assignee has otherwise complied with all of its obligations under the Agreement through the date of this Amendment No. 3. For the avoidance of doubt, it is understood and agreed that transfer from
Assignee to Assignor of the last payment of two hundred fifty thousand U.S. dollars (USD $250,000) pursuant to Amendment No. 2 of the Agreement dated June 18, 2009, is due on July 1, 2010. Assignee hereby acknowledges and confirms
that, to its actual knowledge, Assignor has complied with all of its obligations under the Agreement through the date of this Amendment No. 3. The parties also acknowledge and agree that, pursuant to the Patent Assignment dated November 3,
2008 between the parties, additional patent rights were added as Assigned Patents under the Agreement.

2. The first paragraph of
Section 3, Consideration, of the Agreement is hereby amended and restated to read in its entirety as follows:

As
an inducement to Assignor to execute this Patent Assignment Agreement, Assignee hereby grants to Assignor a royalty-bearing worldwide, co-exclusive (with Assignee) license to use the inventions, ideas and information embodied in the Assigned Patents
solely to develop, make, use and sell products for use as reagents for research purposes only, all of which products shall be considered Covered Products for purposes of this Agreement.

(a) Assignor has the right to sublicense, however only with the prior written consent of Assignee, not to be unreasonably
withheld. In connection with any such sublicense, Assignor shall use its best efforts to ensure that its customers do not use the products for any purpose other than as reagents for research use, and that its sublicensees do not use the inventions,
ideas and information embodied in the Assigned Patents for any purpose other than as reagents for research use (the Scope). Assignor shall promptly notify Assignee in writing if Assignor becomes aware of any actual or potential use by
any of Assignors customers or sublicensees



---

that is beyond the Scope. In connection therewith, Assignor shall, without limitation, regularly and closely monitor the activities of its customers and sublicensees. If Assignor becomes aware of
any such misuse by any of its customers or sublicensees, then Assignor shall immediately provide a written demand to such customer or sublicensee (with a copy to Assignee) to immediately cease all such misuse and, if such customer or sublicensee
does not immediately cease such misuse, Assignor shall immediately terminate the underlying customer or sublicense agreement.

(b) Assignee shall be automatically deemed as, and shall be named, a third party beneficiary under any customer or
sublicense agreement and may enforce the provisions of any such customer or sublicense agreement as if named as the seller or sublicensor thereunder.

(c) For purposes of this Agreement, reagents means UNA amidites, and UNA-containing
oligonucleotides such as UsiRNA constructs.

3. Subsection 3.1.1 of the Agreement is hereby amended and restated to read in
its entirety as follows:

All rights under the Assigned Patents other than those expressly provided in
this Section 3.1 are hereby reserved to Assignee; provided, however, that Assignee may not sublicense the inventions, ideas and information embodied in the Assigned Patents except in connection with the research and/or development
of a therapeutic or diagnostic product(s) of Assignee and/or its sublicensee(s). For the avoidance of doubt, Assignor shall have no right under its license to develop, make, use and sell products intended for therapeutic or diagnostic use.

4. Subsection 3.1.3(b) of the Agreement is hereby amended by deleting the word therapeutic from the third line thereof.

5. As an inducement to Assignor to execute this Amendment No. 3, and in full satisfaction of any and all payment and other obligations
of Assignee due to Assignor under Section 3 of the Agreement on or prior to the date of this Amendment No. 3, Assignee agrees to pay Assignor seven hundred fifty thousand U.S. dollars (USD $750,000), to be due and payable in three
(3) equal payments of two hundred fifty thousand U.S. dollars (USD $250,000) on each of October 1, 2010, January 1, 2011 and April 1, 2011.

6. Exhibit A to the Agreement (Assigned Patents) is hereby amended and restated to read in its entirety as set forth on Exhibit A attached
hereto.

7. For the avoidance of doubt, it is understood and agreed that pursuant to Amendment No. 2 of the Agreement dated June 18,
2009, any and all royalty payment, milestone payment and sublicense revenue sharing obligations of Assignee and any and all due diligence obligations of Assignee pursuant to the Agreement were deleted in their entireties.



2



---

8. To support the licensing efforts of Assignor and Assignee, both parties understand and agree that the
Agreement under confidentiality provision can be shown to potential licensees provided however that the terms (Consideration sections) of the Agreement are redacted.

9. Except as specifically modified by this Amendment No. 3, all provisions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed as of the day and year first above
written.



|                        |  |                       |  |                        |  |        |  |                    
|----------------------- |  | --------------------- |  | ---------------------- |  | ------ |  | -------------------
|ASSIGNOR: 
Ribotask ApS |  |                       |  | ASSIGNEE: 
MDRNA, Inc.
|                        |  |                       |  |                       
|By:                     |  | /s/ Jesper Wengel     |  |                        |  | By:    |  | /s/ Peter S. Garcia
|Name:                   |  | Jesper Wengel, Ph.D.  |  |                        |  | Name:  |  | Peter S. Garcia    
|Title:                  |  | Chairman of the Board |  |                        |  | Title: |  | CFO                



|       |  |                     
|------ |  | --------------------
|By:    |  | /s/ Suzy Lena Wengel
|Name:  |  | Suzy Lena Wengel    
|Title: |  | CEO                 



3



---

EXHIBIT A  ASSIGNED PATENTS



|               |  |                                 |  |                                                                
|-------------- |  | ------------------------------- |  | ---------------------------------------------------------------
|MDRNA
DOCKET # |  | APP. SERIAL #
FILING DATE (FD)  |  | TITLE                                                          
|               |  |                                
|-              |  | PA200800534
FD: 4/11/2008       |  |                                                                
|               |  |                                
|-              |  | PA200700751
FD: 5/22/2007       |  |                                                                
|               |  |                                
|-              |  | PA200701718
FD: 11/30/2007      |  |                                                                
|               |  |                                
|-              |  | PA200701785
FD: 12/14/2007      |  |                                                                
|               |  |                                
|08-07PCT       |  | PCT/US2008/64417
FD: 5/21/2008  |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|               |  |                                
|08-07AU        |  | AU 2008256871
FD: 5/21/2008     |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|               |  |                                
|08-07BR        |  | TBD
FD: 5/21/2008               |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|               |  |                                
|08-07CA        |  | TBD
FD: 5/21/2008               |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|               |  |                                
|08-07CN        |  | CN 200880016977.5
FD: 5/21/2008 |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES



4



---

|        |  |                                |  |                                                                
|------- |  | ------------------------------ |  | ---------------------------------------------------------------
|08-07EP |  | EP 2008780679
FD: 5/21/2008    |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07IL |  | IL 202040
FD: 5/21/2008        |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07IN |  | TBD
FD: 5/21/2008              |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07JP |  | JP 2010-509534
FD: 5/21/2008   |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07KR |  | KR 1020097024222
FD: 5/21/2008 |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07MX |  | MX/a/2009/012568
FD: 5/21/2008 |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07MY |  | PI 20094688
FD: 5/21/2008      |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07NZ |  | NZ 580712
FD: 5/21/2008        |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07SG |  | SG 200907326-3
FD: 5/21/2008   |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07ZA |  | ZA 2009/07529
FD: 5/21/2008    |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-07US |  | U.S. 12/515,403
FD: 5/21/2008  |  | HYDROXYMETHYL SUBSTITUTED RNAOLIGONUCLEOTIDES AND RNA COMPLEXES
|        |  |                               
|08-11P1 |  | U.S. 61/091,165
FD: 8/19/2008  |  | OLIGONUCLEOTIDES AND RNA COMPLEXESWITH UNLOCKED NULCEIC ACIDS  



5